Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Chromocell Therapeutics Corp ( (CHRO) ) has provided an announcement.
Chromocell Therapeutics Corporation has merged into its subsidiary, Channel Therapeutics Corporation, transitioning from Delaware to Nevada jurisdiction. This reincorporation means Channel Therapeutics now holds the assets, rights, and obligations of Chromocell and continues to be listed on NYSE American under the symbol ‘CHRO’. The move includes updates to indemnification agreements for directors and officers, reflecting Nevada laws, and may impact stockholder rights.
See more data about CHRO stock on TipRanks’ Stock Analysis page.